Latest Boardroom Shifts News

Insurance Australia Group (IAG) reported strong FY25 results and upgraded its FY26 guidance, reflecting the completed RACQ acquisition and ongoing strategic growth initiatives.

Brambles Limited reported robust FY25 financial results and sustainability achievements, highlighting a $1 billion free cash flow milestone and ambitious 2030 regenerative targets at its 2025 AGM.

Firebrick Pharma reports a $1.94 million cash reserve after a $1.4 million placement, supporting expanded Nasodine sales across Southeast Asia and the US. Board changes and increased operational costs mark a pivotal quarter for the pharmaceutical innovator.

Cochlear Limited reports steady FY25 financials alongside the launch of its innovative Nucleus Nexa cochlear implant system, setting the stage for projected double-digit profit growth in FY26.

Bellevue Gold Limited reported a robust September quarter with production and sales exceeding expectations, alongside a pioneering net zero emissions milestone. The company is well positioned for growth in FY26 with strategic leadership appointments and improved operational efficiencies.

Deep Yellow Limited reports significant progress on its flagship Tumas Project in Namibia, highlighted by promising high-grade uranium discoveries at the S-Bend prospect and steady advancement of infrastructure and engineering works. Meanwhile, leadership changes and a robust cash position set the stage for the company’s next growth phase.

Deterra Royalties announces the resignation of CEO Julian Andrews by year-end, with Non-executive Director Jason Neal stepping in as interim CEO amid a search for a permanent replacement.

Acumentis delivered a 3.4% revenue increase to $58.1 million at its 2025 AGM, highlighting diversification and a positive outlook for FY26 amid easing inflation and expected rate cuts.

Michael Hill International reported flat earnings in FY25 amid inflation and subdued demand, while new CEO Jonathan Waecker outlines a strategy focused on innovation, AI integration, and margin recovery heading into FY26.

Vitrafy Life Sciences has delivered its first production unit of the next-generation cryopreservation device, advanced its US commercial footprint, and maintained a strong financial position heading into FY2026.

Kingfisher Mining has appointed geologist Chris Bittar as Managing Director, aiming to leverage his expertise to advance its NSW and Western Australian mineral projects.

Nyrada has completed its Phase I trial for Xolatryp, confirming safety and predictable pharmacokinetics, while securing AU$8.25 million to fund an upcoming Phase IIa trial targeting heart attack patients.